SpectraCure AB (DE:2OK)
FRANKFURT:2OK
2OK Stock Chart & Stats
€0.01
€0.03(15.76%)
At close: 4:00 PM EST
€0.01
€0.03(15.76%)
Day’s Range― - ―
52-Week Range€0.00 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)2.59K
Market Cap
€2.76M
Enterprise Value€42.95M
Total Cash (Recent Filing)€16.59M
Total Debt (Recent Filing)€2.19M
Price to Earnings (P/E)―
Beta-80.57
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding570,602,840
10 Day Avg. Volume4,037
30 Day Avg. Volume2,593
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthA very low debt-to-equity ratio (~0.03) materially reduces near-term solvency risk and preserves financial flexibility. Over a 2-6 month horizon this balance-sheet strength supports continued R&D and trial funding capacity and improves negotiating leverage for financing or partnerships.
Focused Clinical IndicationA clear initial indication (prostate cancer) sharpens trial design, regulatory strategy and commercial go-to-market plans. Maintaining a focused development path increases the probability of achieving meaningful clinical milestones and makes resource allocation more efficient over the medium term.
Differentiated Therapeutic PlatformTechnical features like fiber-optic delivery with real-time monitoring create potential clinical differentiation through controlled dosing. Such platform capabilities can be a durable competitive advantage, supporting repeatable protocols and future indication expansion if clinical outcomes validate the approach.
Bears Say
No Revenue / Widening LossesZero reported revenue and sharply larger net losses show the company has not reached commercial scale. Over 2-6 months this structural lack of sales means future value depends entirely on successful clinical progress or financing, increasing execution and funding risk for durable operations.
Persistent Cash BurnSustained negative operating and free cash flow (~-24m to -28.6m) shortens runway and forces dependence on external capital. Persisting cash burn over the medium term risks repeated dilution or constrained R&D/commercial activity if financing terms deteriorate.
Equity Erosion / Negative ROEDeclining equity and a deeply negative ROE (~-0.52 TTM) indicate shareholder value is being eroded by ongoing losses. If losses continue, the deteriorating capital base raises the likelihood of dilutive financings or asset moves, weakening long-term financial resilience.
2OK FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was €0.00 and its highest was €0.16 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is €2.76M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is Aug 14, 2026 which is in 61 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on May 27, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 570,602,840 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in DE:2OK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.